- Biological variation of proprotein convertase subtilisin/kexin type 9 (PCSK9) in human serum2021 | First Faculty of Medicine, Third Faculty of Medicine
- Proprotein convertase subtilisin/kexin type 9 inhibitors in the treatment of a patient with dyslipidemia and myopathy2019 | Third Faculty of Medicine
- Evolocumab, proproteine convertase subtilisin/kexin type 9 inhibitor for intensive treatment of dyslipidemia2016 | Faculty of Medicine in Pilsen
- The Impact of Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies with and without Apheresis on Platelet Aggregation in Familial Hypercholesterolemia2024 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial2020 | First Faculty of Medicine
- Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)2023 | First Faculty of Medicine
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial2020 | Publication without faculty affiliation
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome2020 | Publication without faculty affiliation
- PCSK9 Molecule: Characteristics and Clinical Importance2019 | Third Faculty of Medicine
- Alirocumab, human monoclonal antibody in biological dyslipidemia treatment2016 | Faculty of Medicine in Pilsen
- The treatment of hypercholesterolemia by PCSK9 inhibitors2014 | Faculty of Medicine in Hradec Králové
- Regulation of intracellular metabolism of LDL-cholesterol: the importance of inhibition of PCSK92014 | Faculty of Medicine in Hradec Králové
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia2014 | First Faculty of Medicine
- Monoklonální protilátky v preventivní kardiologii2016 | First Faculty of Medicine
- Alirocumab in treatment of combined dyslipidemia2020 | Third Faculty of Medicine
- Evolokumab v léčbě dyslipidemií se zaměřením na familiární hypercholesterolemii2016 | First Faculty of Medicine
- New possibilities of dyslipidemiaa therapy in patients with familial hypercholesterolemia in secondary prevention - change in reimbursement for PCSK9 inhibitors2021 | First Faculty of Medicine
- PCSK9 inhibitor evolocumab in the FOURIER outcomes trial2017 | First Faculty of Medicine
- Dyslipidemia - the known unknown2023 | First Faculty of Medicine
- Perspectives of further reduction in cholesterol by means of PCSK9 blockade2013 | Faculty of Medicine in Hradec Králové
- PCSK9-9 inhibition in cardiology2016 | Faculty of Medicine in Hradec Králové
- Inhibitors PCSK9 - experience after two years of practice in the Czech Republic2017 | Faculty of Medicine in Hradec Králové
- Léčba dyslipidemie u diabetiků 2. typu2022 | First Faculty of Medicine
- The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?2018 | Faculty of Medicine in Hradec Králové
- Evolocumab - novel options in the treatment of hyperlipidemia2016 | Faculty of Medicine in Hradec Králové
- Hypolipemic therapy in clinical setting2016 | Second Faculty of Medicine
- Hypolipidemická léčba u pacientů s chronickým onemocněním ledvin2022 | First Faculty of Medicine
- Několik postřehů ze studie FOURIER s evolocumabem2017 | First Faculty of Medicine
- New technology in the hypolipidemic drugs development. Inclisiran (LEQVIO)2022 | Faculty of Medicine in Pilsen
- The authors of lipid guidelines are at odds with their own recommendations2017 | First Faculty of Medicine